Sean Salmon serves as Executive Vice President and Group President for the Diabetes Group. In this role, Sean is responsible for the overall strategic direction of the business and its day-to-day global operations.
Sean joined Medtronic in 2004 and has held increasingly senior management roles. Most recently as President of Coronary & Structural Heart within our Cardiac & Vascular Group, he led numerous functions including Clinical, Regulatory, R&D, Quality, Health Economics & Reimbursement, Business Development and Strategy. He led Medtronic’s entry into the highly-competitive drug eluting stent market and subsequently diversified the business via organic innovation and acquisitions. He also led the expansion of Medtronic’s fast-growing transcatheter valve replacement (TAVR) business by commercializing multiple product innovations, extending global penetration and by expanding treatment indications.
Sean has nearly 30 years’ experience in the medical device and pharmaceutical industries, with previous roles at CR Bard, Johnson & Johnson, SurgiVision and EuroRSCG Life. He earned an MBA from the Kellogg School of Management at Northwestern University and a BS in Applied Physiology from Boston University.